Vistagen Therapeutics Stock Price Prediction
| VTGN Stock | USD 3.14 0.02 0.64% |
Oversold Vs Overbought
49
Oversold | Overbought |
EPS Estimate Next Quarter (0.46) | EPS Estimate Current Year (1.60) | EPS Estimate Next Year (1.96) | Wall Street Target Price 13 | EPS Estimate Current Quarter (0.39) |
Using VistaGen Therapeutics hype-based prediction, you can estimate the value of VistaGen Therapeutics from the perspective of VistaGen Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in VistaGen Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying VistaGen because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
VistaGen Therapeutics after-hype prediction price | USD 3.14 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
VistaGen |
VistaGen Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of VistaGen Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in VistaGen Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of VistaGen Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
VistaGen Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting VistaGen Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on VistaGen Therapeutics' historical news coverage. VistaGen Therapeutics' after-hype downside and upside margins for the prediction period are 0.79 and 5.49, respectively. We have considered VistaGen Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
VistaGen Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of VistaGen Therapeutics is based on 3 months time horizon.
VistaGen Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as VistaGen Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading VistaGen Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with VistaGen Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.09 | 2.35 | 0.00 | 0.02 | 9 Events / Month | 2 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.14 | 3.14 | 0.00 |
|
VistaGen Therapeutics Hype Timeline
VistaGen Therapeutics is at this time traded for 3.14. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.02. VistaGen is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -0.09%. %. The volatility of related hype on VistaGen Therapeutics is about 903.85%, with the expected price after the next announcement by competition of 3.16. About 58.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.81. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 0.93. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out VistaGen Therapeutics Basic Forecasting Models to cross-verify your projections.VistaGen Therapeutics Related Hype Analysis
Having access to credible news sources related to VistaGen Therapeutics' direct competition is more important than ever and may enhance your ability to predict VistaGen Therapeutics' future price movements. Getting to know how VistaGen Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how VistaGen Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| UNCY | Unicycive Therapeutics | 0.01 | 6 per month | 6.10 | 0.11 | 14.00 | (7.32) | 41.67 | |
| HOTH | Hoth Therapeutics | (0.04) | 5 per month | 5.09 | 0.08 | 11.36 | (8.16) | 93.34 | |
| TIL | Instil Bio | 0.81 | 9 per month | 6.39 | 0.14 | 20.63 | (10.89) | 105.83 |
VistaGen Therapeutics Additional Predictive Modules
Most predictive techniques to examine VistaGen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for VistaGen using various technical indicators. When you analyze VistaGen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About VistaGen Therapeutics Predictive Indicators
The successful prediction of VistaGen Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as VistaGen Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of VistaGen Therapeutics based on analysis of VistaGen Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to VistaGen Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to VistaGen Therapeutics's related companies.
Story Coverage note for VistaGen Therapeutics
The number of cover stories for VistaGen Therapeutics depends on current market conditions and VistaGen Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that VistaGen Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about VistaGen Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
VistaGen Therapeutics Short Properties
VistaGen Therapeutics' future price predictability will typically decrease when VistaGen Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of VistaGen Therapeutics often depends not only on the future outlook of the potential VistaGen Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. VistaGen Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.4 M | |
| Cash And Short Term Investments | 119.2 M |
Check out VistaGen Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.